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EDITOR’S NOTE:
This is one of 1 of 5 articles generated from the SETAC Pellston Workshop “Ecotoxicological Hazard and Risk Assessment
Approaches for Endocrine-Active Substances (EHRA)” (February 2016, Pensacola, Florida, USA). The primary aim of the
workshop was to provide objective advice, based on current scientific understanding, to regulators and policy makers,
whether in industry, government, or academia. The goal is to make considered, informed decisions on whether to select an
ecotoxicological hazard- or risk-based approach for regulating a given endocrine disrupting substance under evaluation.
ABSTRACT
In the present study, existing regulatory frameworks and test systems for assessing potential endocrine active chemicals are described, and
associated challenges are discussed, along with proposed approaches to address these challenges. Regulatory frameworks vary somewhat
across geographies, but all basically evaluate whether a chemical possesses endocrine activity and whether this activity can result in adverse
outcomes either to humans or to the environment. Current test systems include in silico, in vitro, and in vivo techniques focused on detecting
potential endocrine activity, and in vivo tests that collect apical data todetect possible adverse effects. These test systems are currently designed
to robustly assess endocrine activity and/or adverse effects in the estrogen, androgen, and thyroid hormone signaling pathways; however, there
are some limitations of current test systems for evaluating endocrine hazard and risk. These limitations include a lack of certainty regarding:
1) adequately sensitive species and life stages; 2)mechanistic endpoints that arediagnostic for endocrinepathwaysof concern; and3) the linkage
between mechanistic responses and apical, adverse outcomes. Furthermore, some existing test methods are resource intensive with regard to
time, cost, and use of animals. However, based on recent experiences, there are opportunities to improve approaches to and guidance for
existing testmethods and to reduceuncertainty. For example, in vitrohigh-throughput screeningcouldbeused toprioritize chemicals for testing
and provide insights as to themost appropriate assays for characterizing hazard and risk. Other recommendations include adding endpoints for
elucidating connections between mechanistic effects and adverse outcomes, identifying potentially sensitive taxa for which test methods
currently do not exist, and addressing key endocrinepathways of possible concern in addition to those associatedwith estrogen, androgen, and
thyroid signaling. Integr Environ AssessManag 2017;13:302–316.C 2016 TheAuthors. Integrated Environmental Assessment andManagement
published by Wiley Periodicals, Inc. on behalf of Society of Environmental Toxicology & Chemistry (SETAC)
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INTRODUCTION
Since the late 1990s, individual countries and international
organizations, including Japan, the United States, the
European Union, and the Organisation for Economic
Cooperation and Development (OECD), have initiated
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programs for assessing the potential impacts of endocrine
active substances (EASs) to human health and wildlife.
Although these programs may have originally been devel-
oped independently, their parallel aims have often resulted in
harmonization of test methods (OECD 2010a).
The situation in the United States is broadly illustrative of
the evolution of EAS screening and testing. In 1996, in
response to an increasing number of publications, public
pressure, and media focus, the US Congress mandated that
the US Environmental Protection Agency (USEPA) develop a
screening program to “determine whether certain substan-
ces may have an effect in humans that is similar to an effect
produced by a naturally occurring estrogen, or other such
endocrine effect” (21 U.S.C. § 346a (p)(1-7)). The initial
mandate for assessing estrogen (E)-related effects on humans
was quickly expanded to include wildlife and the androgen
(A) and thyroid (T) signaling pathways. As a result of this
legislation, the USEPA created the Endocrine Disruptor
Screening Program (EDSP), which utilizes a 2-tiered frame-
work, with the 1st tier assessing the potential for a substance
to interact with EAT pathways in vertebrates. Tier 1 includes a
battery of 11 in vitro and in vivo assays that are interpreted
using a weight-of-evidence approach to determine the
potential for endocrine activity of a test substance. In Tier 2
testing, adverse effects and dose–response relationships of
compounds identified as potentially active in Tier 1 are
determined using additionalmammalian and nonmammalian
animal models. The USEPA has also been moving toward
computational models and in vitro high-throughput screen-
ing (HTS) assays to help prioritize and screen chemicals for
endocrine activity. For more information on the USEPA’s
Endocrine Disruptor Screening Program in the 21st century,
please visit https://www.epa.gov/endocrine-disruption/
endocrine-disruptor-screening-program-edsp-21st-century.
Concurrent with the initiation of the EDSP program in the
United States, the OECD established a Special Activity on
Endocrine Disrupter Testing and Assessment to coordinate
the development of test guidelines to detect endocrine
disruptors and to harmonize hazard and risk characterization
approaches (OECD 2010a). This initial effort culminated in
the release in 2002 (updated in 2012) of the Conceptual
Framework (CF) for the Testing and Assessment of Endocrine
Disrupting Chemicals, which outlined a 5-level categorization
(OECD 2012a). Recently, the European Commission issued a
draft proposal for the identification of endocrine disrupting
chemicals, which are criteria that are intended to apply
horizontally to various chemical regulations within the Euro-
pean Union. For more information on the European Commis-
sion’s Endocrine Disruptors Policy, please visit http://ec.
europa.eu/health/endocrine_disruptors/policy/index_en.htm.
In 1998, the Ministry of Environment in Japan initiated their
Strategic Programs on Environmental Endocrine Disruptors,
which outlined policies and measures for studying and
assessing risks associated with EAS perturbation (https://
www.env.go.jp/en/chemi/ed.html). This program was revised
in 2000; then in 2005, the Ministry of Environment released a
new framework, “Perspectives on Endocrine Disrupting
Effects of Substances –ExTEND2005,” which promoted the
conduct of fundamental studies on endocrine disruption and
development of new test methods in cooperation with OECD
and other international groups. ExTEND2005 (Enhanced Tack
on Endocrine Disruption) was replaced in 2010 by EXTEND
(Extended Tasks on Endocrine Disruption) 2010, to accelerate
the establishment and implementation of assessment meth-
ods and to identify priority chemicals and areas of research. In
contrast with the EDSP in the United States, neither the
Japanese programs nor the OECD CF are prescriptive in
the context of regulatory activity, but, rather, they outline
information and tools or research for evaluating the hazards of
EASs and informing risk assessment.
In the time since the US, OECD, European Union, and
Japanese programs were first created, availability of test
systems for assessing potential endocrine activity and disrup-
tion has substantially increased (e.g., see http://www.oecd.
org/chemicalsafety/testing/seriesontestingandassessmentte
stingforendocrinedisrupters.htm for a list of OECD guidance
documents for assessing endocrine disruptors). Although
these newer (and still emerging) methodologies often
represent a significant advancement and improvement over
historic toxicity testmethods in thecontextof EASassessment,
they nonetheless have potential shortcomings, including: (1)
large resource requirements; (2) uncertainty relating to data
interpretation in the context of linking mechanistic to apical
data, accounting for non–endocrine-related toxicity, among
others; (3) uncertainty in design aspects relative to the
selection of most relevant species, strains, life stages, and
endpoints; and (4) limitations in available technical expertise
and training needed to conduct the tests. Later we examine
the current test systems for assessing EASs, illuminate
potential limitations and weaknesses associated with these
test systems, and propose improvements and future research
that would move the global evaluation of EASs forward, to
better inform the assessment of both hazard and risk
associated with these compounds.
The emphasis of the Pellston workshop that served as the
genesis of the present study was on ecological hazard and
risk assessment, which generally is focused on adverse
effects at the population level, often for a large number of
species. Although this differs from the individual-level
emphasis in human health assessments, it is important to
recognize that screening and testing programs for EASs are
inherently integrative across, at least, vertebrate species.
For example, many of the in silico and in vitro systems used
for hazard assessment are based on mammalian (primarily
human and rodent) data or test systems, or both. Further,
some of the in vivo nonmammalian assays used for
screening for endocrine activity (e.g., in EDSP Tier 1) also
are intended to serve as “triggers” for possible higher-tier
testing in mammalian systems (USEPA 1998). This is
justified by the strong phylogenetic conservation of the
hypothalamic-pituitary-gonadal/thyroidal (HPG/T) axes
across vertebrate species. In any instance, it is not feasible
to consider ecological hazard and risk assessment for EASs
in isolation from efforts focused on human health.
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CURRENT TEST SYSTEMS FOR ASSESSING
ENDOCRINE ACTIVITY
In silico methods
A practical 1st step for examining a substance’s potential
for endocrine activity, especially for substances with little
toxicity or mode of action data, is to collect available
information based on reliable quantitative structure–activity
relationships (QSARs) and read-across approaches from
chemical analogues. An example tool for this type of an
assessment is the Estrogen Receptor (ER) Expert Systemused
by the EDSP, which is a database compiled into a decision
tree for determining ER binding potential (http://archive.epa.
gov/med/med_archive_03/web/html/er.html). The publi-
cally available Oasis LMC QSAR (http://oasis-lmc.org/)
contains ER and androgen receptor (AR) binding affinity
QSARs, as well as models to predict chemical effects on
cytochromeP450 aromatase (CYP19), an enzyme responsible
for a key step in the biosynthesis of steroid hormones. The
OECD Toolbox, which is publically available freeware
developed with the scientific and financial assistance of
OECD and the European Union, is also an in silico QSAR
platform for filling gaps in toxicity data and grouping
substances into chemical categories (http://www.oecd.org/
chemicalsafety/risk-assessment/theoecdqsartoolbox.htm).
The Danish QSAR Database (http://qsar.food.dtu.dk) is
another example of publically available freeware that
includes estimates from more than 200 QSARs, including
more than 600000 substances andmodels for ER, AR, thyroid
receptor, and pregnane X receptor binding. These QSAR-in
silico tools are useful for preliminary data collection steps to
guide subsequent in vitro and in vivo screening and testing
for potential endocrine activity. The OECD provides
general guidance on the validation principles and potential
regulatory use of QSAR tools (OECD 69; Supplemental
Table S1).
In vitro assays
Currently, the EDSP Tier 1 battery includes a total of 5 in
vitro assays that assess ER and AR competitive binding, ER
transcriptional activation, and effects on steroidogenesis and
aromatase. The OECD CF for Level 2 suggests the use of
the same assays, but also provides a basis for expanding the
number and types of in vitro systems that could be
considered as they are developed and validated (OECD
2012a). A complete description of the various in vitro EDSP
assays, as well as suggestions pertaining to their staging and
conduct, is provided by Borgert et al. (2011). In addition,
Scholz et al. (2013) provide an overview of several in vitro
tests for the assessment of EASs in fish and amphibians.
The USEPA ToxCastTM program uses a suite of more than
700HTS in vitro assays that cover approximately 300 signaling
pathways and provide the basis for a framework to assist in
ranking and prioritizing chemicals for future testing (http://
www.epa.gov/chemical-research/toxicity-forecasting). A sub-
set of the ToxCast assays evaluates potential impacts on EAT
signalingpathways. TheEPAEDSP recentlyproposed that this
subset couldbeused to identify chemicals that display specific
endocrine activities of concern and that this information, in
conjunction with rapid exposure assessment techniques,
could be used for prioritization of chemicals for Tier 1 testing.
A limited practical demonstration of this approach that uses
approximately 20 HTS assays focused on chemicals that
interact with mammalian (primarily human) ER isoforms has
been described, and recently it was reviewed by an external
advisory group to the EDSP (Browne et al. 2015; Federal
Register Notice 2015).
In vivo methods
Some in vivo assays (e.g., those at OECD CF Level 3 or
EDSP Tier 1) primarily provide screening for possible
endocrine activity. They are designed to provide a qualitative
(yes or no) indication of perturbed EAT signaling as a
consequence of direct interactions with a receptor or
enzyme. A prototypical example is induction of vitellogenin
(VTG; egg yolk protein precursor) in male fish by ER agonists,
an endpoint included in several fish assays, including those
described inOECDTG229 and 230 (Supplemental Table S1).
Indirect effects such as changes in sex steroid synthesis or
thyroid hormone production alsomay be detected in someof
the shorter-term in vivo assays. These mechanism-oriented
assays do not generally expose organisms for a large
proportion of their life cycle, and therefore are incapable
of revealing the full spectrum of possible effects. Assays at
this level are designed primarily for hazard identification in
the context of indicating perturbation of specific HPG/T
pathways. A positive outcome in these screening assays
indicates a possibility for adverse effects in reproductive or
developmental endpoints, or both, in longer-term tests (e.g.,
OECD CF Levels 4 and 5 or EDSP Tier 2). The results from
these in vivo screens are used in a weight-of-evidence
analysis to decide whether and how higher-tier in vivo tests
should be performed. Some guideline examples of in vivo
endocrine screening studies are the 21-day FishAssay (OECD
TG 230), the Fish Short-Term Reproduction Assay (FSTRA;
OECD 229; OPPTS 890.1350), the Amphibian Metamorpho-
sis Assay (AMA; OECD TG 231; OPPTS 890.1100), the
Hershberger Bioassay in Rats (OECD TG 441; OPPTS
890.1400), and the Rodent Uterotrophic Assay (OECD TG
440;OPPTS 890.1600). These test guidelines are fully listed in
Supplemental Table S1.
Slightly longer-term and/or more comprehensive tests (in
terms of endpoints) at the OECD CF Level 4 typically are
sensitive to more than 1 mode of action and include apical
endpoints potentially suitable both for hazard and for risk
assessment. Because they have numerous endpoints, the
criteria for a positive result in termsof endocrine activity canbe
morecomplex thanat lower levels. Becauseof thenumberand
diversity of endpoints evaluated, Level 4 testsmay also help to
determine the relative sensitivity of endocrine-mediated
effects as compared with effects of general toxicity (e.g.,
Ankley and Jensen 2014). Some Level 4 assays can provide
data on adverse effects, whichmay be sufficient for identifying
points of departure for hazard or risk assessment, or both.
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However, most do not provide more comprehensive informa-
tionaboutpossibleendocrinedisruptingeffects atmultiple life
stages, such as those obtainable from life-cycle experiments
(OECD CF Level 5). Some guideline examples of OECD CF
Level 4 studies include the Fish Sexual Development Test
(FSDT; OECD 234), the Larval Amphibian Growth and
Development Assay (OECD 241; OCSPP 890.2300), and the
Pubertal Development and Thyroid Function Assay in
Peripubertal Male and Female Rats (US EPA OPPTS
890.1500 and 890.1450, respectively). These test guidelines
are fully listed in Supplemental Table S1.
Full life-cycle andmultiplegenerational studiesat theOECD
CF Level 5 provide data on adverse effects and are especially
useful for risk assessment because they add to the weight of
evidence concerning potential impacts in humans and
vertebrate wildlife. The effects observed may be caused by
endocrine disruption or other mechanisms. Life-cycle and
multigenerational tests include the evaluation of longer-term
exposures during multiple windows of potential susceptibility
to EASs, including maternal transfer to offspring, early
development, sexual differentiation, and active reproduction;
thus, there is a higher level of confidence about negative
results. Some guideline examples of OECDCF Level 5 studies
are theMedaka ExtendedOneGeneration Reproduction Test
(OECD 240, OCSPP 890.2200) and the Extended One-
Generation Reproductive Toxicity Study in Rats (OECD 443).
These test guidelines are fully listed in Supplemental Table S1.
Nospecific test guidelines exist for characterizingendocrine
activity in invertebrates; however, several tests could at least
partially indicate perturbations of endocrine function through
evaluation of apical endpoints. The Enchytraeid Reproduction
Test (OECD 220) and the Earthworm Reproduction Test
(OECD 222) broadly represent the Phylum Annelida. Arthro-
pods are represented by the Daphnia magna reproduction
test (OECD TG 211), the Mysid Chronic Toxicity Test (OPPTS
850.1350), the Developmental Toxicity to Dipteran Dung
Flies (OECD228), thePredatoryMiteReproductionTest in Soil
(OECD 226), the Collembolan Reproduction Test in Soil
(OECD 232), the Sediment-Water Chironomid Toxicity
Using Spiked Sediment/Water (OECD 218 and OECD 219,
respectively), and the Sediment-Water Chironomid Life-Cycle
Toxicity Test Using Spiked Water or Spiked Sediment (OECD
233). In addition, 2 molluskan test guidelines on reproductive
toxicity (Lymnaea stagnalis [OECD 243] and Potamopyrgus
antipodarum [OECD 242]) were recently adopted by the
OECD. These test guidelines are fully listed in Supplemental
Table S1.
RESOURCE DEMANDS FOR ENDOCRINE
SCREENING AND TESTING
One of the major issues in the context of the routine use of
in vivo EDSP Tier 1/OECD CF 3/4 assays involves resources.
This is particularly true when large numbers of chemicals
need to be evaluated, such as the 10000þ substances under
consideration in the United States. Although slight differ-
ences exist, guideline studies required or recommended by
the EPA, OECD, European Union, and Japanese programs
for EAS screening and testing are essentially the same, so the
following discussion about resources, although focused on
the EDSP as an illustration, is applicable to programs
throughout the world. The cost of conducting the entire
battery of 11 EDSP Tier 1 screening assays was estimated
originally at US$500000 to US$800000 per chemical, with
current estimates at closer to $1 million per chemical.
Following the 1st round of EDSP Tier 1 testing, The USEPA
recommended further testing for 18 chemicals of the 52
(35%) evaluated in the Tier 1 battery (USEPA 2016).
Individual nonmammalian EDSP Tier 2 (OECD Level 4/5)
tests have considerably larger projected costs per study, with
estimates in the order of US$300000 to US$350000, US
$400 000 to US$450000, and US$300000 to US$650000,
respectively, for the Larval Amphibian Growth and Develop-
ment Assay, the Medaka Extended One Generation Repro-
duction Test, and the Avian Two-Generation Toxicity Test.
Thus, if required, higher-tier tests would quickly and
significantly add to the costs of EAS assessment on a per-
chemical basis.
Guideline tests also can take a significant amount of time
for scheduling and completion. For example, to conduct the
FSTRA (OECD229), theremay be a wait time to rear sufficient
numbers of fish from in-house cultures to the appropriate age
for testing (i.e., 4.5–6 months old). In addition to the actual
study period (i.e., a minimum 14-d pre-exposure phase
followed by a 21-d exposure), considerable data collection
and analysis occurs after the end of the FSTRA exposure, with
biochemical analyses and histopathology requiring an
additional 4 to 6 weeks. Some test chemicals also possess
challenging physicochemical properties that may require
nonroutine approaches for test solution preparation for
aquatic testing. For example, the desire to avoid using
solvents in testing canmean the development of solvent-free
exposure systems for aquatic tests, which can add time and
resources to the program.
Finally, EAS test batteries can require a significant number
of animals. For example, the EDSP Tier 1 battery of
mammalian and nonmammalian assays uses 600 animals
per test substance (Bishop and Willett 2014). Additional
animals are also often required for dose range–finding
studies, additional groups in pre-exposure to ensure suffi-
cient numbers meet test performance criteria, and experi-
ments that need to be repeatedwhen a first attempt does not
meet performance criteria.
Resource issues may become less problematic as informa-
tion is gathered relative to endpoints or tests that are not
informative or, possibly, redundant for the purposes of EAS
screening. For example, Ankley and Gray (2013) evaluated
data frommethod validation studies with 12model EASs that
have activity as ER agonists, AR agonists, AR antagonists, or
inhibitors of different steroidogenic enzymes. All the
chemicals had been tested in the FSTRA and in 1 or more
of the 4 in vivo EDSP Tier 1 screens with rats. In most cases
there was high concordance between the fish and the rat
assays with respect to identifying chemicals that impacted
specific endocrine pathways of concern, reflecting strong
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structural and functional conservation of the HPG axis across
vertebrates. The model EASs produced positive pathway-
specific responses in the fish and 1 or more of the rat assays.
However, some assays were clearly superior to others in
terms of detecting specific pathways; for example, the effects
of inhibitors of steroid hormone synthesis were most obvious
in the FSTRA, whereas the activity of AR antagonists was
clearest in the Hershberger and male pubertal assays. Based
on this analysis, it appears possible to use just 2 of the current
Tier 1 tests, the FSTRA and themale pubertal assay, to ensure
full coverage of HPG axis pathways of concern. For example,
Ankley and Gray (2013) proposed that these 2 tests could
serve as initial “gatekeeper” assays, following which chem-
icals with negative findings may be exempt from further
testing or, if positive, subjected to additional, confirmatory
analyses with other relevant EAS assays. This would greatly
enhance throughput of chemicals through initial testing, both
in terms of resource utilization and timing.
Greater use of HTS data also should help address resource
limitations relative to EAS screening and testing. As noted
earlier, the EDSP is utilizing data from a battery of 18 ER-
oriented HTS assays integrated into a computational model
as a basis for prioritizing chemicals for more expensive and
intensive Tier 1 testing (Browne et al. 2015). The accuracy of
the ER computational model was 84% to 100% for predicting
uterotrophic responses (Browne et al. 2015). This ER
computational model was applied to 1812 commercial and
environmental chemicals (which included 45 ER-positive and
-negative reference chemicals), and a total of 111 chemicals
(6.1%) were predicted to be strongly ER active (Judson et al.
2015). Expansion of this basic approach to encompass a suite
of other endpoints relevant to perturbation of the HPG/T
axes, as well as other potential toxicity pathways, has
significant promise. As shown through the EDSP ER
demonstration project, this type of approach could be
used to prioritize chemicals for testing, based on the degree
of their interaction with HPG/T targets of concern. In addition
to theHTS assays for ER interactions, several existing ToxCast
assays capture chemical interactions with the AR and
enzymes involved in steroid synthesis such as CYP19
(Karmaus et al. 2016). High-throughput screening of chem-
icals for effects on steroidogenesis using human H295R
adrenocortical carcinoma cells indicated that of the 2060
chemicals evaluated, 411 (20%) showed effects on at least 1
hormone in the steroidogenesis pathway evaluated (Karmaus
et al. 2016). Additional assays amenable to HTS are being
developed for other endocrine targets, including the HPT
axis (Paul-Friedman et al. 2016). Although most existing HTS
assays relevant to the HPG/T axes are based on mammalian
systems, the high degree of cross-species conservation of
structural and functional aspects of key endpoints (e.g., ER,
AR) suggests that these systems should also be useful for
nonmammalian vertebrates, at least at the level of screening
and prioritizing chemicals for endocrine activity (LaLone et al.
2013; Ankley et al. 2016).
As a simple example or proof of concept of the application
of HTS data, an analysis of the activity of the model AR
agonist 17b-trenbolone (TRB) was conducted using data
from the ToxCast HTS suite, and it found that the androgen
was positive in 9 of the 10 assays designed to detect AR
interactions (Figure 1). TRB also displayed some degree of
activity in ToxCast assays with the progesterone receptors
and ERs, which is consistent with the available knowledge
relating to in vivo behavior of TRB in vertebrates, including
fish. If TRB were an “unknown” chemical that exhibited this
profile, it would be prioritized above other chemicals not
displaying these types of interactions for further in vivo
testing.
An additional use of HTS data in terms of optimizing
resources would be to help select the individual assays and
endpoints best suited for the generation of higher-level in
vivo data to support regulatory decision making for EASs as
opposed to conducting, for example, the entire battery of
EDSP Tier 1/2 (or OECD Levels 3–5) assays. For example,
based on the TRB analysis, one would conclude that
invertebrate tests would likely not be required for a chemical
with this profile, becausemost invertebrates do not appear to
have a functional ER or AR (LaLone et al. 2013; Ankley et al.
2016). Instead, it would be most appropriate to consider
using ER- andAR-mediated developmental and reproductive
endpoints, and test designs such as the FSTRA or FSDT.
Given the apparent sensitivity of the FSDT to androgens
(Knacker et al. 2010), onemight decide that this would be the
optimal choice for further in vivo testing of the chemical of
concern.
INTERPRETATION OF RESULTS FROM ENDOCRINE
SCREENING AND TESTING
Assessments of environmental risk and hazard for EASs are
unique compared with those historically conducted for other
classes of chemicals, in that concerns raised relate to not only
possible individual- or population-level adverse effects
(Marty et al. this issue), but also the mechanistic basis via
Figure 1. ToxCast data for 17b-trenbolone (data download February 2016).
Molecular targets of the ToxCast assays that showed positive responses are
listed on the y-axis. The points on the graph indicate AC50 values that
correspond to the concentrations listed on the x-axis. Thedashed line indicates
the lower cytotoxicity limit, and the solid line indicates the median cytotoxicity
response. AR¼ androgen receptor; Cyp¼ cytochrome P450; ER¼ estrogen
receptor; GPCR¼G protein–coupled receptor; GR¼glucocorticoid receptor;
MR¼mineralocorticoid receptor; PR¼progesterone receptor.
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which these effects occur. This is the foundation of legislated
mandates behind most EAS screening and testing programs,
and has necessitated the development of both screening-
level assays and endpoints that enable identification of
chemical perturbation of a given molecular target and tests
that identify the possible negative consequences of this. This
has sometimes resulted in a conceptual “disconnect”
between the results of lower-tier and lower-level mechanistic
assays and data from studies focused on apical responses,
which often do not include collection of extensive mechanis-
tic data. As a consequence, there may be no assurance that
endocrine activity of a chemical determined in vitro or in
short-term in vivo assays (EDSP Tier 1; OECD CF Tiers 2/3) is
indeed the basis of adverse apical responses measured in
longer-term assays (EDSP Tier 2; OECD CF Tiers 4/5). Some
EAS assays such as the FSDT (OECD 234) feature the
simultaneous collection of both mechanistic and apical data
that can help inform this linkage (Ankley and Jensen 2014),
but most existing endocrine assays do not, leaving the
association between pathway perturbation and downstream
responses uncertain. A conceptual framework that can help
bridge this gap is the adverse outcome pathway (AOP;
Ankley et al. 2010), which aims to depict causal, not
correlational, linkages between perturbation of a molecular
initiating event (MIE), such as receptor activation or inhibi-
tion, and the subsequent cascade of biological responses
(or key events) that culminate in negative impacts on
individuals or even populations. Various publications have
described AOPs and AOP networks that could support EAS
hazard and/or risk assessment in the context for establishing
linkages across biological levels of organization (e.g., Ankley
et al. 2009; Knapen et al. 2015).
For risk assessment it may not be imperative to establish
and evaluate intermediate key events linking an MIE to an
adverse outcome in anAOP, but this process becomes critical
when conducting hazard assessments in which decisions may
be based on linkage of a specific MIE perturbation (e.g., ER
activation) to a discrete population-relevant adverse effect
(e.g., reduced fecundity). Becker et al. (2015) discuss the
application of Bradford-Hill considerations in assessing the
strength of an AOP. Results from the approach outlined by
Becker et al. (2015) can guide researchers toward additional
data collection to either strengthen an existing AOP or
investigate other lines of evidence that may be contributing
to observed adverse effects.
For study designs that assess the potential for endocrine
activity, it may be advisable to collect additional endpoints to
better characterize the MIE and intermediate key events
associated with adverse outcomes. Primary target organs of
EASs in vertebrates include multiple segments of the HPG/T
axes including the hypothalamus-pituitary plus the primary
endocrine glands: the thyroids, adrenal-type tissues, para-
thyroids, pineal glands, pancreatic islets, and gonads. Other
tissues and organs such as the liver, heart, and adipose
tissue have secondary endocrine functions that may also
be targeted by EASs (Schug et al. 2013). Yet, many studies
focus on a limited number of targets, most commonly the
thyroid and gonads for analysis of biochemical or molecular
endpoints. Only limited information is available on the effects
of EASs on other potential targets, such as the adrenals
(interrenal and chromaffin tissue in fish), which have been
identified as commonly affected and vulnerable endocrine
organs (Bergman et al. 2013). Adrenals and interrenals play a
critical role during development but are also active in
metabolism and, therefore, present a particularly effective
target for assessing effects of EASs. Coady et al. (2014)
suggest various additional tissue sampling procedures to
maximize the mechanistic information that would be
available for assessment following the conduct of an FSTRA
or an AMA. For example, liver and kidney tissue could be
preserved for potential histopathological investigations to
assess whether adverse effects are due to systemic toxicity. In
addition, any remaining fish blood plasma (i.e., not used to
quantify circulating levels of VTG) could be analyzed for
changes in sex steroid concentrations, which can be
especially informative for some chemicals that cause endo-
crine disruption through inhibition of steroid synthesis
(Ankley et al. 2009; Mihaich et al. this issue). Preserving
additional tissues and fluids for potential future investigations
and storing surplus animals from long-term studies can be
particularly useful for collecting data on additional mecha-
nistic and histopathological endpoints. This approach also
has positive ethical aspects in regard to animal testing
because it optimizes the use of the individual organisms.
Utilization of an AOP-based framework to establish
credible linkages between mechanistic and diagnostic
measurements and relevant apical outcomes represents 1
approach for effectively discerning whether endocrine
perturbation by a given test chemical may actually be
responsible for observed adverse effects in a test. A
complementary approach to the evaluation of potential
MIE involves the use of HTSdata, such as that collectedby the
ToxCast program, which could provide insights as to
potential nonendocrine biological activity of unknown
chemicals. In other instances, HTS data for an unknown
chemical may produce responses indicative of perturbation
ofMIEs associated withmultiple toxicity pathways, only some
of which involve endocrine function (Mihaich et al. this issue).
TEST SPECIES AND LIFE-STAGE SELECTION FOR
ENDOCRINE SCREENING AND TESTING
The current internationally approved in vivo test guidelines
addressing endocrine effects have been developed in a few
model test species selected primarily for pragmatic rather
than ecological reasons. Therefore, the extrapolation of test
data to all other species, even within a given phylogenetic
group, may not always be appropriate. For example, in the
case of amphibians, only 1 species, Xenopus laevis, is used in
guideline toxicity tests. This species is aquatic in all life
stages, and therefore it might not be adequately representa-
tive of amphibians with different life strategies. Similarly, in
avian reproduction testing, only precocial species (i.e.,
mallard duck and quail, which are well-developed at hatch)
are used in standard avian toxicity tests. The altricial strategy
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in avian development, which includes most songbirds
(passerines) and birds of prey, is not represented in standard
avian reproduction test guidelines. Altricial hatchlings
depend on intensive parental care, which may enhance their
sensitivity to EASs that affect behavior (Jaspers 2015). Thus, it
is important to consider the genetic, physiological, and
ecological traits of laboratory species used in EAS screening
and testing, and how these speciesmay or may not represent
wild populations when attempting to extrapolate laboratory
findings to environmental populations and communities
(Segner 2011).
In other instances, test guidelines may be completely
lacking for potentially sensitive phyla. For example, guideline
tests on reptiles have not yet been developed, although
possible endocrine-mediated adverse effects have been
observed in the field (Guillette et al. 1999), and temperature-
dependent sex determination could make some species in
this class particularly vulnerable to endocrine disruption
during development (Bergeron and Crews 1998). Test
guidelines that can screen for and identify endocrine activity
in invertebrates are somewhat lacking. The limitations of
the invertebrate tests in OECD CF are well described in
footnote 4 of the CF document (OECD 2012a, p. 4): “At
present, the available invertebrate assays solely involve
apical endpoints which are able to respond to some
endocrine disrupters and some non-EDs. Those in Level 4
are partial life-cycle tests, while those in Level 5 are full- or
multiple life-cycle tests.” The 2 new mollusk reproduction
tests do not change this overall picture because they do not
include endocrine-specific endpoints, although they cover
endocrine-mediated reproductive effects in mollusks such as
aquatic snails.
Fish are by far the best represented nonmammalian
vertebrate taxa in terms of EAS assays. However, the 3
main model species used in fish EAS guideline toxicity tests
represent warm freshwater, fractional spawning teleost fish
with relatively short generation times (Supplemental
Table S2). They do not represent marine species, pelagic
species, cartilaginous fish, and the diversity of reproductive
strategies occurring among fish including viviparity (live
breeding), seasonal spawners, and species with extremely
high fecundity. For example, in Atlantic cod (Gadus morhua),
a single female spawns millions of eggs, so a very minor
reduction in fecundity could potentially be less impactful at
the level of the population in comparison with fish species
that produce larger and fewer eggs. In viviparous fish, such as
the eelpout (Zoarces viviparus), the exposure scenario of the
embryos is different from the oviparous test species.
Chemicals could accumulate because of maternal transfer,
affecting the sensitivity of the species and the metabolism of
the chemical. For example, malformations in eelpout
embryos after maternal exposure to 17a-ethynylestradiol
have been reported (Morthorst et al. 2014).
Among the commonly used small fish species in EAS
screening, there are life history and morphological differ-
ences that can cause differential sensitivity to perturbation of
different endocrine pathways (Supplemental Table S2). For
example, zebrafish gonads initially develop as ovaries, but
then in male fish, the ovarian tissue degenerates and the
testis develop (Takahashi 1977; Maack and Segner 2003).
This period of juvenile hermaphroditism in the zebrafish may
explain the increased sensitivity of the sex ratio endpoint for
this species in comparison with other fish species exposed to
AR agonists such as TRB during critical developmental
windows. For example, concentrations around 10ng TRB per
liter cause irreversible phenotypic sex reversal in zebrafish
when exposed during early life stages (Holbech et al. 2006;
€Orn et al. 2006; Morthorst et al. 2010), whereas the same
exposure concentrations do not cause similar effects in
Japanese medaka or Western mosquitofish ( €Orn et al. 2006;
Sone et al. 2005). However, in assays focusedon reproductive
success, there can be limitations to using the zebrafish
because sexually mature male zebrafish do not have
androgen-responsive secondary sex characteristics as do,
for example, fathead minnows and Japanese medaka. In
particular, the observation of female fish withmale secondary
sex characteristics is diagnostic for AR agonists (Ankley and
Jensen 2014; Borgert et al. 2014). Thus, test species and life-
stage selection are important elements to consider for
endocrine screening and testing (Parrott et al. this issue).
With preliminary information on the endocrine mode of
action from QSAR predictions or HTS in vitro assays, more
informed decisions on species selection and life stage can be
made before in vivo testing; however, in many cases,
additional information on the natural history and ecological
traits of species of concern are needed to understand how
endocrine effects observed in laboratory test species will
apply toward species in the field.
To increase output of information regarding sensitive life
stages with a minimum investment of effort, it may be
advisable to combine standard study designs. This could
entail, for example, adding a fish early-life-stage test (OECD
210) to a fish full-life-cycle test. This combination would allow
for the assessment of maternal transfer to the F1 generation if
deemed necessary based on knowledge of physicochemical
properties of a test substance, such as the propensity to
bioaccumulate. Depending on the specific question to be
addressed, the F1 generation could be exposed to the same
concentration as the F0 generation or reared under control
conditions. Analogously, the FSTRA (OECD 229; OPPTS
890.1350) could be combined with the FSDT (OECD 234).
This approach would allow for the assessment of both the
activational (e.g., reproduction) and the organizational (e.g.,
sexual development) aspects of the fish life cycle, without
actually conducting a fish full-life-cycle test.
TEST DESIGN CONSIDERATIONS FOR
ENHANCING CURRENT ENDOCRINE ACTIVE
SUBSTANCE ASSAYS
Test sensitivity and power
From a statistical perspective, a design limitation that is
particularly relevant to EAS testing is the complexity of the
current in vivo assays in terms of the number and variety of
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endpoints, animal groupings, and sampling schedules. For
example, both fish and avian multigenerational studies can
have greater than 40 distinct endpoints distributed among
the sexes and generations. This can result in hundreds of
statistical comparisons, the breadth of which often requires
the simultaneous use of several different statistical methods.
Additionally and importantly, the large number of endpoints
tends to greatly increase the likelihood of Type 1 errors.
Another potential design limitation relevant to aquatic animal
studies involves the statistical unit. If animals are to be housed
in groups of 2 ormore individuals, then these test subjects are
considered to be interdependent, and consequently the unit
of analysis will be, with few exceptions, the contained group
rather than the individual. Statistically, this requirement can
be managed by increasing the number of replicates relative
to the group sizes. The inclusion of multiple replicates not
only improves the power of the assay, it instills confidence to
the findings and avoids the potential influence of “tank
effect” on study outcome. However, for a large study, this can
cause the number of tanks (and tankmaintenance) to become
untenable.
Although it is evident that some of the aforementioned
design limitations cannot be easily rectified, others can be
avoided by judicious planning. For example, issues of
unintended bias can be mitigated by the masking of group
identities and randomization of all study variables that cannot
be held constant (e.g., Wolf et al. 2015). Power analysis can
be performed a priori to estimate the optimal number of
replicates andgroup sizes to be used for a given study. If a no-
observable effect concentration is to be determined, then a
power analysis should be performed during the study design
phase to ensure sufficient power to find a toxicologically
important effect. If a point estimate of an effect concentration
is to be estimated, then a sensitivity analysis should be
conducted to determine that an x%effect can be estimated, if
it occurs, with a confidence interval that is not so wide as to
render the estimate meaningless. For example, in a power
analysis conducted during the validation of the FSDT (OECD
234), a minimum of 4 replicate tanks containing 30 embryos
each was suggested for achieving sufficient power to detect
15% to 25% phenotypic sex reversal (when the genetic sex of
the fishes was known). The same design would have sufficient
power to detect a 31% change in sex ratio when the genetic
sex of the fishes is not known (OECD 2012b). Such power
analyses should be based on relevant historical data,
information gleaned from published literature, or if neither
is available, on the results of a preliminary range-finding
study. Some reports of historical control data for endocrine
screening studies (i.e., FSTRA and AMA) are now available in
the peer-reviewed literature (Coady et al. 2014; Schapaugh
et al. 2015), and they could be productively used to further
optimize design of the assays.
Concentration selection
Testing for EASs is historically unique in that there is
concern not only for adverse effects but also for the AOP via
which these effects occur. In this context, the selection of
appropriate doses and concentrations is imperative for
examining potential endocrine activity and effects that occur
apart from potential systemic toxicity. For in vitro assays, the
analogue for systemic toxicity observed in animal assays is
cytotoxicity. Currently, in vitro EDSP and OECD guidelines
allow up to 20% cytotoxicity, which is a level that could
potentially confound results. The level of allowable cytotox-
icity could be lowered to address this potential issue.
For example, for cell-based assays, the Interagency Coordi-
nating Committee on the Validation of Alternative Methods
has recommended that only concentrations that do not
cause greater than 10% cytotoxicity should be included in the
analysis (Interagency Coordinating Committee on the
Validation of Alternative Methods and National Toxicology
Program Interagency Center for the Evaluation of Alternative
Toxicological Methods 2003).
In the USEPA guideline for the FSTRA (OPPTS 890.1350),
the criteria for the highest test concentration is either the
maximum tolerated concentration (defined as one-third the
96-h LC50), the limit of solubility, or 100mg test chemical per
liter. In a review of the first 52 chemicals that were evaluated
in the Tier 1 EDSP (USEPA2013), therewere several examples
where in vivo overt toxicity at the highest concentration in the
FSTRA confounded the interpretation of effects. The USEPA
concluded that “the use of a 1/3 the LC50 value sometimes
resulted in substantial mortality as well as effects on physical
appearance, behavior and/or changes in body weight”
(USEPA 2013, p. 97 of 160). Changing the current guidance
to using one-tenth the LC50 and/or other available data to
set the highest test concentration has been recommended as
a solution (Wheeler et al. 2013) and has already been
implemented in endocrine assays with fish, for example, the
Medaka Extended One Generation Reproduction Test
(OECD 240, OCSPP 890.2200) and the FSDT (OECD 234).
However, the test concentration setting for these higher-tier
tests encompassing all life stages should undoubtedly use all
available chronic data and targeting range-finding strategies.
A toxicokinetic (TK) approach could also be used to guide
concentration selection in endocrine screening and testing.
Application of TK approaches for dose setting in ecotoxicol-
ogy studies is rare. However, this approach has a long history
of application in drug development and has become more
common across mammalian toxicology in an effort to
harmonize an approach for identifying a maximum tolerated
dose (European Centre for Ecotoxicology and Toxicology of
Chemicals 1996; USEPA 2003). In brief, the aim of this
approach is to identify the highest level that does not exceed
linear pharmacokinetics in plasma. The use of excessively
high doses or concentrations can create TK processes that
result in a systemic exposure to either parent compound or
metabolites that no longer increases with increasing dose, or
a systemic exposure that hugely increases with a small
increase in dose. Exceedingly high doses and associated
nonlinear TK will likely produce results that are not relevant
for hazard or risk assessments. Consequently, the driver for
adoption of the TK approach for dose setting in mammalian
toxicology studies has been to improve testing and
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assessment methodologies to investigate a specific mode of
action (e.g., carcinogenicity or endocrine disruption) and not
confound the interpretation for human relevance (Boobis
et al. 2008). Creton et al. (2012) discuss practical examples
that underscore the role TK can play in improving study
design and interpretation through selection of appropriate
high doses. One of the barriers to the application of TK in
ecotoxicology would be development of improved sampling
methods and analytical capabilities, but this would be a
highly productive area of research for the aquatic and wildlife
toxicology community in general.
In addition to setting the high concentration and dose
in an EAS test system, the selection of the range of doses or
test concentrations and the spacing of intervals is an
important consideration. In the FSTRA and the AMA, for
example, a minimum of 3 concentrations (plus negative
control) are recommended (see OECD 229, OECD 231,
OPPTS 890.1100, and OPPTS 890.1350). A range of spacing
factors between 3.2 and 10 are suggested, with a minimum
test concentration differential between the highest and
lowest of 1 order of magnitude. The spacing of test
concentrations in any test can be affected by the limit of
quantification of the analytical capability available for the test
substance of interest. Difficulties can arise when water
solubility and/or biological effects occur at low levels that
approach the limits of quantification. Using a 10-fold spacing
between concentration levels may lead to difficulties in
quantifying the lowest concentration level, and thus closer
spacing may be desired. In contrast, the maximum dose
separation of 10-fold may be preferable to ensure that there
are at least 2 concentrations in the FSTRA and the AMA that
are free from overt toxicity if the highest concentration is
affected in this way (Coady et al. 2014). Furthermore, using a
dose separation of up to 10-fold enables the inclusion of
lower concentrations that may have greater environmental
relevance. Including low, environmentally relevant concen-
trations in study designs can increase the confidence in the
study findings in regard to their applicability for environmen-
tal risk assessments. Furthermore, including additional
concentration groups in the study design (e.g., testing 5
concentrations rather than the minimum requirement of 3)
could enhance the test design for determining no-observable
effect concentration and/or effect concentration values for
use in environmental risk assessments. However, this
approach should be balanced against animal use consider-
ations and the intended purpose of a particular assay or test
(screening or concentration–response derivation for risk
assessment).
As is evident from this discussion, there is a pressing need
for more guidance for concentration selection in EAS
screening and testing. The specific challenge of identifying
potential endocrine activity in the absence of the confound-
ing effects of systemic toxicity requires careful consideration.
A concentration setting guidance document developed
through collaborative and harmonized efforts could reduce
uncertainty and guidemore refinedendocrine assessments in
the future.
Analytical confirmation and aquatic delivery of test
substances
Measuring concentrations of test chemicals in dosing
media is a critical factor in determining the acceptability of in
vivo screening assays and definitive tests for EASs, particu-
larly when attempting to translate laboratory data into an
environmental setting. Because of the extreme potency
of some EASs (e.g., tributyltin, steroids such as TRB or
17a-ethynylestradiol), this can present challenges for both
analytical method development and exposure of test
organisms. In some instances, low, environmentally relevant
concentrations can be problematic when no-observable
effect concentrations are approaching (or lower than) the
analytical limits of quantification (Mensink et al. 2002; Ankley
et al. 2003). Steroids such as TRB can also be composed of
stereoisomers. Accounting for this in analytical method
development is especially pertinent when multiple stereo-
isomers display endocrine activity (e.g., Jensen et al. 2006).
Managing analytical challenges may require significant
resources (including time) to develop the necessary techni-
ques, validate appropriate laboratory and analytical meth-
ods, and understand exposure dosing and conditions, a
necessity that often is underappreciated in EAS testing. This
includes consideration of possible changes in the efficiency of
chemical delivery over the course of longer-term assays,
where, for example, changes in the microbial degradation of
chemicals can cause significant temporal decreases in
chemical concentration. In addition, major metabolites
formed during in vivo exposures should be screened for,
and potentially identified, in solutions and biological samples
(tissues from exposed organisms). For some chemicals, it is
the metabolites rather than the parent chemical that possess
significant endocrine activity. This information can help to
inform the interpretation of endpoints and future biological
assays. Finally, robust quality assurance and control proce-
dures are necessary for establishing confidence in test
chemical measurement (and isomers and metabolites identi-
fication), particularly in longer-term studies; this encom-
passes many considerations, including identification,
quantification (e.g., 4-point mass spectrometry identifica-
tion), recovery, and reproducibility. All of these factors are
critical drivers in the overall limit of quantification value for an
analytical method, as well as for continually improving
analytical technologies.
The use of organic cosolvents historically has been an
acceptable means to deliver test substances in aquatic
testing (OECD2000). However, there aremany advantages in
using techniques that eliminate the use of cosolvents,
including decreasing the possibility of testing above the
functional limit of water solubility, reducing the potential for
low dissolved oxygen levels caused by increased microbial
biomass (because ofmicrobial metabolism of some solvents),
reducing the use of animals (elimination of a solvent control
group), and decreasing the potential for toxicological
interactions between a cosolvent and a test chemical.
Elimination of cosolvent use through techniques such as
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generator columns for solids or liquid–liquid saturators for
liquids has become a recommended option for EAS testing
(e.g., see OECD 229, OPPTS 890.1350, OECD 321, OPPTS
890.1100, OECD 240, and OCSPP 890.2200). Although this
can supply superior test data, additional time may be
required when testing to optimize appropriate solvent-free
delivery techniques associated with column size, water flow
rate, chemical loading regimens, among others. It may also
be necessary to accept that the exposure conditions using
solvent-free techniques maybe more variable than might be
achieved using solvent delivery techniques.
LABORATORY CAPABILITIES FOR ENDOCRINE
SCREENING AND TESTING
The relatively recent development in the field of ecotoxi-
cology of regulatory test protocols that include mechanistic
endpoints, that is, those indicative of endocrine function,
requires a level of scientific and technical expertise beyond
that previously needed in most contract testing situations.
Further, these types ofmechanisticmeasurements often have
been validated in only a small number laboratories or by a few
people, early in the adoption of new methodology, which
means there often is no or only limited historical control data
to evaluate the expertise of the individual or team learning
the new methodology.
The key to developing and learning new techniques and
methods is clear communication among researchers who
develop methods and those who implement or transfer the
methods. The communication can take many forms, such as
the inclusion of bold text warnings on portions of methods
thatmust be strictly followed, providingmean and SD targets
for specific endocrine endpoints, and/or video training that
clearly demonstrates a critical step or technique for a
procedure. For some methods, transfer of technical informa-
tion also can be facilitated through hands-on workshops. As
new methods develop and are successfully implemented
across other laboratories, it becomes important to periodi-
cally review the error rate and method or endpoint precision
and share historical control databases (Coady et al. 2014;
Schapaugh et al. 2015).
Many endpoints that are informative of the endocrine
mechanism of action (e.g., VTG protein or mRNA levels,
gonadal histopathology, and plasma sex steroids) may be
prone to measurement error because of the technical
expertise and expert judgment required for providing quality
data. It is illustrative to consider VTG measurements as an
example of the challenges that can occur when requiring
testing laboratories to adopt nonroutine endpoints. The
immunoassays typically used for VTG protein determination
in samples from EAS tests with fish (e.g., OECD TG 229, 230)
have not been routinely used in most testing laboratories.
Commercial kits are available for VTGs that could be used as
means of normalizing reported values; however, these exist
only for a limited number of species and, probably most
importantly, can be costly when processing a large number of
samples. This has resulted in the development of many in-
house assays, some of which have not followed robust
validation procedures, which can cause unanticipated
variability in measured VTG values across different laborato-
ries. Another potential issue relative to VTGmeasurements is
that of basic immunoassay performance over time even
within a given laboratory, which can be compromised by
changes in the availability of specific (i.e., antibodies or
labels) and nonspecific (i.e., serum albumins or extraction
solvents) reagents. As an example, average plasma VTG
protein concentrations in female fathead minnows measured
via a commercially available homologous ELISA kit (Biosense
Fathead Minnow Vitellogenin ELISA kit; Bergen, Norway)
varied more than 10-fold across 11 different FSTRA studies
conducted in the same laboratory (Table 1). This likely was
due to multiple factors, including inherent variability of VTG
levels among individual female fish (e.g., Jensen et al. 2001),
the variability in the ELISA kit performance, and the variability
associated with different laboratory technicians conducting
the assay. Based on a post hoc power analysis, the power to
detect 20% to 80% decreases in female VTG varied from 5%
to 99% across 11 different studies (Table 1). This analysis
indicates that additional replication in the test design and/or
an alternative, possibly less variable method of measuring
VTG concentrations (e.g., Zhang et al. 2004)may be called for
to strengthen the power of the VTG endpoint in EAS assays
with fish.
Histopathological assessment of gonadal tissue in fish,
amphibians, or birds, or of thyroid tissue in amphibians or
birds can be another problematic endpoint. In this regard,
although technical issues (e.g., sample dissection, preserva-
tion, staining, among others) can lead to poor-quality
material, a key problem often encountered is the misinter-
pretation of pathological findings because of insufficient
training in lower animal endocrine toxicologic pathology
(Wolf et al. 2015). To this end, more guidelines on best
practices are needed, especially involving species for which
this has not been a routine endpoint in the past. Although a
number of high-quality histopathology guidance documents
have been generated by the OECD and USEPA (e.g., OECD
2010b), these tend to be static references that might benefit
from online publication in a database or atlas format that can
be continuously updated. An additional recommendation for
this endpoint is the inclusion of pathology peer review
(evaluation of a subset of the slides by a 2nd pathologist) as a
quality-control measure, particularly for instances in which
the results are equivocal, unanticipated, and/or controversial.
KNOWLEDGE GAPS IN ENDOCRINE SCREENING
AND TESTING
A significant data gap for understanding EAS hazards is the
lack of fundamental knowledge concerning endocrine path-
ways for many invertebrate species. Part of the difficulty in
addressing this is related to the vast number of invertebrate
species that exist, combined with the great diversity this
group displays in the endocrine control of growth, develop-
ment, and reproduction. Because of this lack of understand-
ing, an unfortunate trend in the field has been for some to
assume that the same indicators of endocrine activity in
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vertebrates (e.g., VTG induction by estrogens in fish) also
apply to invertebrates, which often is not the case. For
example, the transcriptomic response of the Vtg2 gene in
Daphnia magna is not elevated in response to chemicals with
known estrogenic modes of action in vertebrates (Hannas
et al. 2011), and there is no valid evidence that vertebrate sex
steroids have endocrine or reproductive roles in mollusks
(Scott 2013). Consequently, there is a pressing need for
research to support development of invertebrate-specific
EAS screens and tests. As a 1st step in understanding the
endocrine system of these ecologically important phyla, it is
imperative to molecularly and functionally characterize the
numerous nuclear receptors that are present. Recently
available high-throughput sequencing (e.g., oyster genome)
and genome mining tools can speed up this process and
develop useful assays for hazard and risk assessment (Zhang
et al. 2012).
Another significant gap in understanding the effects of
endocrine disruptors is in the consideration of other relevant
endocrine pathways in vertebrates. From an HPG perspec-
tive, most attention has been on soluble nuclear hormone
receptors, but little attention, if any, has been given to
membrane receptors for sex steroid hormones, including
ERs, ARs, and progestin receptors. These receptors have
been described for mammals and fish, and have been shown
to regulate reproduction through oocyte maturation and
sperm motility, among other mechanisms (Thomas et al.
2006). Further, work that originated first in Europe has shown
that reproductive effects from exposure to progestinsmay be
a major concern for fish (Zeilinger et al. 2009), frogs (S€afholm
et al. 2012), and birds (Tell et al. 1999). Synthetic progestins,
such as levonorgestrel, used in the birth control pill are found
in the environment (Lopez de Alda et al. 2002). Concern has
also been raised about glucocorticoids in the environment
and their action on the hypothalamic-pituitary-interrenal axis
in aquatic vertebrates. Fish, like other vertebrates, produce
endogenous corticosteroid hormones such as cortisol in
interrenal cells located in the head kidney (Mommsen et al.
1999). As in other vertebrates this natural corticosteroid binds
to glucocorticoid receptors, which work as transcription
factors to regulate genes involved with glucose metabolism,
stress response, the immune system, blood pressure, and
osmoregulation (Weyts et al. 1999; Aluru and Vijayan 2009),
among other endpoints. Glucocorticoids are used for human
and veterinary purposes to treat a broad group of disorders
including skin allergies, asthma, and rheumatic disease,
among others, and can occur in the environment at nano-
grams to micrograms per liter (ng/L to mg/L) concentrations.
Synthetic glucocorticoids can have a variety of in vivo effects
in fish from altering plasma glucose levels, to destabilizing
the hypothalamic-pituitary-interrenal axis (Kugathas and
Sumpter 2011; LaLone et al. 2012; Nesan and Vijayan
2013; Nakayama et al. 2014), and even depressing repro-
duction (Schreck 2010) by decreasing VTG synthesis in the
liver and consequently egg production.
New sensitive analytical methods using nontargeted
approaches have identified many more contaminants thanTa
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previously anticipated in receiving waters. When these
methods are coupled with bioanalytical tools to measure
biological effects in surface waters, it is clear that contam-
inants exist at concentrations high enough to affect the
function of several endocrine-related receptors (Escher et al.
2014). Among some of the activities measured are the
nuclear factor erythroid-related factor 2 involved with
oxidative stress, peroxisome proliferator-activated receptors
a and g involved in fatty acid metabolism, aryl hydrocarbon
receptor involved in CYP induction, retinoic acid receptor
(RAR) isoforms (RARa, RARb, RARg) involved with retinoic
acid–related events, retinoid-related orphan receptor b, and
retinoic-X receptor b involved in thyroid signaling (Escher
et al. 2014), all of which could interfere with endocrine-
related endpoints. Several of these receptors have been
studied in relation to fish reproduction (peroxisome prolif-
erator-activated receptors: Cheshenko et al. 2008; RARs:
Lubzens et al. 2010; retinoic-X receptor: Habibi et al. 2012).
Although 2 of these receptors are often associated with non–
endocrine-mediated toxicity, aryl hydrocarbon receptor and
Nrf2, they perhaps should not be discounted because
significant cross talk between ER and aryl hydrocarbon
receptor has been described in the literature that shows
disruption of VTG production in fish (Bemanian et al. 2004),
and between aryl hydrocarbon receptor and Nrf2 that is
related to developmental embryo toxicity (Rousseau et al.
2015). Developing screening assays for activity through these
receptors may be beneficial when trying to decipher the
endocrine-related effects on whole organisms from expo-
sures to individual chemicals that appear not to follow
canonical AOPs.
In addition, the close relationship between the endocrine
and the immune systems of organisms needs to be better
evaluated to help explain phenomena such as morbidity in
fish and disease outbreaks in avian populations exposed to
complex mixtures that include EASs. The head kidney is
involved in the production of cortisol and catecholamines, as
well as hematopoiesis and other immune functions (Weyts
et al. 1999). Sex steroids are known to play immunomodula-
tory roles in fish, and exposure to contaminants may make
fish more sensitive to pathogens (reviewed by Milla et al.
2011). Similarly, the thymus, which plays a critical role in the
immune response of higher vertebrates, is a known target of
endogenous estrogens (Zoller and Kersh 2006). For example,
exposure of European sea bass (Dicentrarchus labrax) to
exogenous estrogens was recently reported to affect thymic
growth and regionalization in juveniles, which may have
persistent consequences for the immune function of adults
(Seemann et al. 2015).
More research is also required to better define AOPs
for various classes of chemicals commonly tested for
possible endocrine activity, and current protocols and test
guidelines should be strengthened to help differentiate
between endocrine and nonendocrine modes of action
(Mihaich et al. this issue). Also, a better understanding is
needed concerning the effects of nonchemical stressors on
endocrine function. For example, in female rainbow trout
(Oncorhynchus mykiss), confinement stress decreases VTG
levels resulting in reduced egg size and significantly lower
survival rates for progeny (Campbell et al. 1994). The inability
to differentiate between the effects of physical or social stress
and those caused by an EAS may greatly confound data
interpretation and require the evaluation of additional
endpoints to ensure the true cause is understood. Strength-
ening the understanding of AOPs should enable the use of
molecular endpoints in screening assays to classify test
chemical modes of action, thereby directing subsequent
testing and potentially eliminating some of the high-cost
assays that are now required.
Finally, many HTS assays that are (or could be) used to
categorize and screen chemicals are based on mammalian
(largely human) nuclear receptors and associated assays
(e.g., Browne et al. 2015). To support use of these types of
assays to predict endocrine functional endpoints in non-
mammalian vertebrates, there is a need to conduct
systematic research to examine cross-species structural and
functional conservation of key MIEs, and develop, where
necessary, HTS reporter assays with, for example, fish
receptors (e.g., Ankley et al. 2016). A few assays already
exist for some receptors that illustrate the efficacy of using
this approach (Liu et al. 2005; Sabo-Attwood et al. 2007), and
there is a whole fish embryo bioassay for estrogenic
chemicals (Brion et al. 2012). More research should be
devoted to developing more of these types of assays and
making them commercially available.
CONCLUSION
There has been substantial scientific advancement through
the development and implementation of the testing and
hazard and risk assessment approaches to evaluate potential
adverse effects though an endocrine mechanism. In particu-
lar, the existing test systems and frameworks that have been
developed for assessing EASs via interaction with the EAT
pathways are relatively comprehensive for identifying and
assessing potential endocrine effects. However, opportuni-
ties now exist to retrospectively examine the lessons learned
from the recent implementation of these efforts to improve
the reliability and relevance of endocrine assessments.
Priority areas that were identified included:
 leveraging information to the extent possible from HTS
assays to prioritize and inform testing programs;
 utilizing in silico and in vitro data, and experience with
existing assays as a basis for modifying screening and
testing frameworks to optimize resource use;
 developing additional approaches to address species
sensitivity, sensitive life stages, and critical endpoints to
improve the predictive ability to detect an adverse effect
at the population level; and
 identifying gaps that can be addressed by research to
improve testing paradigms.
It is impossible to address every uncertainty, and currently
available test systems are relatively robust for addressing
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endocrine modalities that operate through the EAT path-
ways. However, implementing the recommendations out-
lined in the present study will move us in the direction toward
reducing uncertainty in testing and assessment approaches
that evaluate potential adverse effects exerted though an
endocrine mechanism.
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